This slide show highlights the 2015 FDA approvals of cancer treatments, which included therapies for melanoma, RCC, sarcoma, and lung, breast, and pancreatic cancers, as well as various hematologic malignancies.
Forging a Path in Thoracic Surgery to Create a Stellar Career
Rian M. Hasson Charles, MD, MPH, FACS, has a first-of-its-kind role at Brigham Women’s Hospital that will focus on health equity.
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer
Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.
Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope
Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.
Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC
The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.
Osimertinib/Chemo Yields Favorable OS Trend in EGFR-Mutated NSCLC
Treatment with osimertinib plus chemotherapy also shows a consistent survival benefit across prespecified NSCLC subgroups in the phase 3 FLAURA2 trial.